REGENERON PHARMACEUTICALS Q2 RESULTS BEAT EXPECTATIONS

Trending News ☀️

According to Regeneron Pharmaceuticals’ ($NASDAQ:REGN) press release, the company’s Q2 non-GAAP EPS of $9.77 beats expectations by $1.02. Additionally, revenue of $2.86B beats by $60M. These strong results suggest that the company is on track to continue its success in the future. Given the positive results of this quarter, it is likely that Regeneron Pharmaceuticals’ market and earnings will continue to grow in the long term.

Market Reaction

REGENERON PHARMACEUTICALS reported better-than-expected results for the second quarter, sending the stock up 5.9% on Wednesday. Despite the positive news, most news coverage of the company has been negative. The company’s stock opened at $600.0 and closed at $608.8 on Wednesday, up from its last closing price of $575.0.

VI Analysis

REGENERON PHARMACEUTICALS is a company with strong fundamentals that reflect its long term potential. The company’s VI Star Chart shows that it is strong in asset, profitability, growth, and weak in dividend. REGENERON PHARMACEUTICALS has a high health score of 8/10 with regard to its cashflows and debt, meaning it is capable of paying off debt and funding future operations. The company is classified as a ‘gorilla’, a type of company that achieved stable and high revenue or earning growth due to its strong competitive advantage. At the right price, it is suitable for those who want to invest for high capital gains.

However, high growth companies are deemed more risky as they attempt to grow faster.

Summary

Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. The company’s products include EYLEA injection, Praluent injection, Dupixent injection, Libtayo injection, and Kevzara injection. The stock price rose 5.9% following the release of the results.